| Analysts were expecting Endo Pharmaceuticals Holdings Inc. (ENDP) [Chart - News - Analysis] to report earnings of $0.65 for last quarter, but ENDP missed expectations with actual earnings of $0.63---2 cents below the consensus estimate. ENDP also issued earnings guidance for next quarter that is in line with current analyst expectations. If you compare last quarter's earnings to the $0.64 the company made per share during the same quarter a year ago, you can see that ENDP’s earnings are down this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare ENDP's 10.54% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 16.82% for the Drug Manufacturers - Other industry as a whole during that same time frame, you can see that analysts expect ENDP to underperform the industry in the future---which is a bad sign for the stock. Drilling down a little deeper into the Drug Manufacturers - Other industry, you can see how analysts believe ENDP will stack up against some of the other stocks in the industry, like Novo Nordisk A/S (NVO) [Chart - News - Analysis] and Dr. Reddy's Laboratories Ltd. (RDY) [Chart - News - Analysis], in the future. Analysts believe NVO's earnings are going to grow at a rate of 19.83% while RDY's earnings are going to grow at a rate of 21.00%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
